HK inno.N is fast-tracking the South Korean launch of ecnoglutide, a GLP-1 receptor agonist licensed from China’s Sciwind Biosciences. Following recent approvals in China for both type 2 diabetes and obesity, attention is shifting to whether this newcomer can compete with established giants like Wegovy and Zepbound. HK inno.N has completed patient enrollment for its domestic Phase 3 trial and aims to submit a marketing authorization application as early as this year.
The Numbers: Weight Loss vs. Differentiation
In its Chinese Phase 3 clinical trials, ecnoglutide demonstrated an average weight loss of 15.1% over 48 weeks. While this figure is respectable, it does not surpass the leading injectables currently dominating the global market.
However, Sciwind and HK inno.N are playing a "differentiation card." Ecnoglutide is the world’s first cAMP-biased GLP-1 receptor agonist. By selectively acting on the cyclic adenosine monophosphate (cAMP) pathway—a key intracellular signaling messenger—the drug aims to offer superior "durability" in weight loss and improved management of metabolic risk factors. According to Sciwind, the treatment also shows promise in refining fasting blood glucose, uric acid levels, and blood pressure.
The Race to a 2027 South Korean Launch
The bridging Phase 3 trial in South Korea, known as project ‘IN-B00009,’ is nearing its final stages. HK inno.N met its enrollment target of 315 participants just four months after the trial began in early 2026.
The primary endpoints for the Korean trial are set at the 40-week mark, assessing the percentage of body weight change and the proportion of patients achieving at least 5% weight loss. This timeline is slightly more aggressive than the 48-week benchmark used in the Chinese trials, suggesting a push for a swift regulatory review.
A Crowded Market: The Challenge of Timing
Despite the promising science, HK inno.N faces a steep uphill battle. By the time ecnoglutide hits the South Korean market—expected in 2027—the landscape will be incredibly crowded.
Injectable Competition: Novo Nordisk, Eli Lilly, and Hanmi Pharmaceutical are all expected to have established products on the market.
The Rise of Orals: Oral options like the "Wegovy pill" and Lilly’s "orforglipron" are projected to launch in Korea as early as next year, offering 15–20% weight loss with the added convenience of a tablet.
Industry experts suggest that ecnoglutide’s success will hinge on "real-world" data from China. If the drug can prove that its weight-loss effects last longer or carry fewer metabolic side effects than its competitors, it may yet find a significant niche in the South Korean market.
